| Previous Close | 77.63 |
| Open | 77.79 |
| Bid | 0.00 x |
| Ask | 0.00 x |
| Day's Range | 77.53 - 78.57 |
| 52 Week Range | 56.59 - 79.44 |
| Volume | 707,211 |
| Avg. Volume | 728,773 |
| Market Cap | 11.12B |
| Beta | 0.82 |
| PE Ratio (TTM) | 34.40 |
| EPS (TTM) | 2.28 |
| Earnings Date | Jul 26, 2017 - Jul 31, 2017 |
| Dividend & Yield | 1.32 (1.68%) |
| Ex-Dividend Date | 2017-05-09 |
| 1y Target Est | 66.73 |
Zacks•6 days agoResMed (RMD) at 52-Week High: What's Driving the Stock?
Share price of ResMed Inc. (RMD) scaled a new 52-week high of $79.22 on Jun 19, eventually closing a bit lower at $78.91.
- Investor's Business Daily•11 days ago
Sleep Apnea Treatment Provider Enters New Buy Zone
A Relative Strength Rating upgrade for Resmed shows improving technical performance. Will it continue?
- Market Realist•16 days ago
FDA Approval Boosts Baxter’s Generic Injectable Business
On June 7, 2017, Baxter International announced FDA approval and the commercial launch of its Clindamycin injection in saline.
